araag2/HINT huggingface dataset:
Clinical trial NCT00684177 (phase 3, status: completed)
Conditions: skin infections, bacterial
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: retapamulin ointment, 1%, placebo ointment
SMILES: [H][C@]12CC[C@]([H])(C[C@]([H])(C1)SCC(=O)O[C@]1([H])C[C@@](C)(C=C)[C@@]([H])(O)[C@]([H])(C)[C@]34CCC(=O)[C@@]3([H])[C@@]1(C)[C@]([H])(C)CC4)N2C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  subject is aged 2 months or older

          -  subject has secondarily-infected traumatic lesion (laceration, sutured wound or
             abrasion)

          -  negative urine pregnancy test

          -  subject has total skin infection rating scale score of at least 8, including
             pus/exudate score of at least 3

          -  subject and/or parent/legal guardian is willing and able to comply with protocol

          -  subject or parent/legal guardian has given written informed consent or assent as
             applicable

        Exclusion criteria:

          -  previous hypersensitivity to pleuromutilin

          -  secondarily-infected animal/human bite or puncture wound

          -  subject has an abscess

          -  chronic ulcerative lesion

          -  underlying skin disease

          -  systemic signs and symptoms of infection

          -  infection not appropriately treated with topical antibiotic

          -  infection requires surgical intervention prior to or during study

          -  subject received systemic antibacterial or steroid, or topical therapeutic agent
             within 24 hours of entry into study

          -  serious underlying disease

          -  subject pregnant, breast feeding or planning a pregnancy, or unacceptable method of
             contraception

          -  other investigational drug within 30 days of study entry

          -  subject previously enrolled in this study
Clinical trial NCT00409838 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, methotrexate, placebo, abatacept, methotrexate
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Rheumatoid arthritis (RA) for longer than 1 year from the time of the initial
             diagnosis of RA

          -  Patients must have been taking methotrexate for at least 3 months with at least a
             weekly dose of 15 mg, and a stable dose for 28 days prior to treatment (Day 1)

          -  Methotrexate weekly dose as low as 10 mg is permitted for patients who cannot tolerate
             higher doses

        Key Exclusion Criteria:

          -  Evidence (as assessed by the Investigator) of active or latent bacterial or viral
             infections at the time of potential enrollment
Clinical trial NCT00305188 (phase 3, status: completed)
Conditions: metastases, colorectal neoplasms, colorectal carcinoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: xaliproden (sr57746a), placebo, oxaliplatin, 5-fluorouracil, leucovorin
SMILES: FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC3=CC=CC=C3C=C2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        Main inclusion criteria :

          -  Histologically or cytologically-proven metastatic cancer of the colon or rectum.

          -  Metastatic disease not amenable to potentially curative treatment (eg: inoperable
             metastatic disease).

          -  Male or female aged >18 years.

          -  WHO Performance Status (PS) : 0 or 1.

          -  Measurable disease.

          -  No prior chemotherapeutic regimen for metastatic disease.

          -  Disease-free interval from end of adjuvant therapy of at least 6 months (1 year if
             oxaliplatin was part of the adjuvant therapy).

          -  Prior radiotherapy is permitted if it was not administered to target lesions
             identified for this study - unless progression within the radiation portal is
             documented - and provided it has been completed at least 3 weeks before randomization.

          -  Signed written informed consent prior to study entry.

        Exclusion Criteria:

        Main exclusion criteria :

          -  Any condition or past medical history that contra-indicates treatment with oxaliplatin
             and 5-FU, as reported in approved labeling information.

          -  Received chemotherapeutic agents other than 5-FU, LV, Levamisole, irinotecan,
             capecitabine, oxaliplatin as part of adjuvant therapy.

          -  Peripheral neuropathy >Grade 1.

          -  Concomitant treatments with drugs/ingredients reported to have a potential activity in
             preventing peripheral sensory neuropathy.

          -  Concurrent active cancer originating from a primary site other than colon or rectum.

          -  Presence of any symptom suggesting brain metastasis.
Clinical trial NCT00622284 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo identical to bi 1356 5mg, placebo identical to glimepiride 1mg or 2mg or 3mg or 4 mg, bi 1356, glimepiride
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously
             treated with metformin alone or with metformin and one other oral antidiabetic drug

          2. Glycosylated haemoglobin (HbA1c) 6.0 - 9.0% at screening for patients treated with
             metformin and one other oral antidiabetic drug

          3. HbA1c 6.5 - 10.0% at screening for patients treated with metformin alone

          4. HbA1c 6.5 - 10.0% at beginning of the placebo run-in phase

        Exclusion criteria:

          1. Myocardial infarction, stroke or transient ischemic attack (TIA)

          2. Impaired hepatic function

          3. Renal failure or renal impairment

          4. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening

          5. Treatment with insulin or glucagon-like peptide 1 (GLP-1) analogue/antagonists within
             3 months prior to screening
Clinical trial NCT00717561 (phase 3, status: completed)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: avelox (moxifloxacin, bay12-8039), ceftriaxone; azithromycin; amoxicilline/clavulanate; clarithromycin
SMILES: [H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O, [H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO
Eligibility criteria:

        Inclusion Criteria:

          -  Hospitalized non-ICU patients (age, >= 18 years)

          -  Clinical signs and symptoms of CAP, with PSI score IV or V

          -  Radiologically confirmed evidence of a new and/or progressive infiltrate(s)

          -  Requirement for initial parenteral therapy

          -  At least 2 of the following conditions:

               -  Productive or non productive cough with or without purulent or mucosus or
                  mucopurulent sputum

               -  Dyspnea and/or tachypnea (respiratory rate of > 20 breaths/min)

               -  Rigors and/or chills

               -  Pleuritic chest pain

               -  Auscultatory findings of rales and/or crackles on pulmonary examination and/or
                  evidence of pulmonary consolidation

               -  Fever (an oral temperature of >= 38 °C, a rectal temperature of >= 39 °C, or a
                  tympanic temperature of >= 38.5 °C) or hypothermia (rectal or core temperature of
                  < 35 °C), and a WBC count of >= 10,000 cells/mm3 or >= 15% immature neutrophils
                  bands; regardless of peripheral WBC count) or leukopenia (total WBC count of <
                  4500 cells/mm3)

          -  Written informed consent

        Exclusion Criteria:

          -  PSI Class I-III and V with need for ICU admission

          -  Hospitalization for > 48 hours before developing pneumonia, or discharge from hospital
             < 30 days prior. Note: patients currently residing in residential long-term facilities
             can be enrolled in the study
Clinical trial NCT00440466 (phase 3, status: completed)
Conditions: anemia, renal diseases
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin alfa, epoetin alfa, epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O, OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O, OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet the diagnostic criteria for chronic kidney disease, defined as a glomerular
             filtration rate (GFR) >=15 mL/min per 1.73 m2 and <60 mL/min per 1.73 m2 (Stages 3 and
             4) as calculated by the central laboratory

          -  Hemoglobin level between 10.0 and 11.9 g/dL during the 4 weeks before randomization

          -  History of increase in hemoglobin after the initial dose

          -  Stable dose of epoetin alfa given once-weekly before randomization.

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Iron deficiency

          -  iron overload

          -  severe congestive heart failure

          -  Active infection

          -  Recent heart attack, Stroke or blood clot.
Clinical trial NCT00145470 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: asenapine, placebo
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have bipolar I disorder, current episode manic or mixed

          -  Treated with lithium or valproic acid

        Exclusion Criteria:

          -  Have an unstable medical condition

          -  Clinically significant laboratory abnormality.

          -  Have a primary diagnosis other than bipolar I disorder.
Clinical trial NCT00210717 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or
             undifferentiated types) according to the Diagnostic and Statistical Manual of Mental
             Disorders, 4th edition (DSM IV) for at least 1 year before the screening evaluation

          -  a total PANSS score of 60 to 120 at screening and baseline (pre-treatment) evaluations

          -  a body mass index (BMI [weight (kilograms)]/[height (meters)]²) of at least 15.0 kg/m²
             .

        Exclusion Criteria:

          -  A primary active DSM-IV Axis I diagnosis other than schizophrenia

          -  a decrease of 25% or more in the total PANSS score between screening and baseline
             evaluations

          -  a DSM-IV diagnosis of active substance dependence within 3 months of screening
             evaluation

          -  a history of treatment resistance as defined by failure to respond to 2 adequate
             trials of different antipsychotic medications

          -  a woman who is pregnant, breast-feeding, or planning to become pregnant during the
             study period.
Clinical trial NCT00099242 (phase 3, status: completed)
Conditions: alzheimer's disease, dementia, alzheimer type
ICD codes: G30.8, G30.9, G30.0, G30.1, G30.8, G30.9, G30.0, G30.1
Drugs: rivastigmine transdermal patch
SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of dementia of the Alzheimer's type

          -  Males, and females who are surgically sterile or one year postmenopausal

          -  A primary caregiver willing to accept responsibility for supervising the treatment

        Exclusion Criteria:

          -  Any condition (other than Alzheimer's) that could explain patient's dementia

          -  An advanced, severe or unstable disease that may put the patient at special risk

          -  Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular
             disease
Clinical trial NCT01529541 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: anagliptin, sitagliptin
SMILES: CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who had diagnosed with type 2 DM before 3 months

          -  Men and women between the age of ≥ 19 and ≤ 75 years

          -  FPG ≤ 270 mg/dL at screening visit

          -  Patients who consent to participate in this trial by written Informed Consent Form

        Exclusion Criteria:

          -  Type 1 DM or secondary diabetes

          -  Subjects who are administrating oral anti-hyperglycemic drugs or have to take a
             medicine

          -  Body mass index < 20 kg/m2 or > 40.0kg/m2

          -  Subjects who are assessed to be inappropriate for this trial by investigator
Clinical trial NCT00368108 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: 2 mg perampanel, 4 mg perampanel, placebo comparator
SMILES: O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1, O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1, [Na+].[Cl-]
Eligibility criteria:

        INCLUSION CRITERIA:

          1. Male or female patients with idiopathic Parkinson's Disease fulfilling the United
             Kingdom (UK) Parkinson's disease Society Brain Bank diagnostic criteria 7, with a good
             response to levodopa.

          2. Patients must have been diagnosed with idiopathic PD at > 30 years of age.

          3. Patients must have predictable motor fluctuations of the wearing "OFF" type.

          4. Patients must rate between II-IV on the Hoehn & Yahr scale when in an "OFF" state.

          5. Patients must be taking optimized levodopa therapy.

        EXCLUSION CRITERIA:

          1. Pregnant or lactating women.

          2. Women of child bearing potential unless infertile (including surgically sterile) or
             practicing effective contraception (eg, abstinence, intrauterine device or barrier
             method plus hormonal method). These patients must have a negative serum beta-human
             chorionic gonadotrophin (B-HCG) test at the Screening visit, and a negative urine
             pregnancy test at the Baseline visit (Day 0). These patients must also be willing to
             remain on their current form of contraception for the duration of the study.
             Postmenopausal women may be recruited but must be amenorrheic for at least one year to
             be considered of non-child bearing potential as determined by the Investigator.

          3. Patients with a past or present history of drug or alcohol abuse as per Diagnostic and
             Statistical Manual - 4th edition (DSM IV) criteria.

          4. Patients with a past (within one year) or present history of suicidal ideation or
             suicide attempts.

          5. Patients with unstable abnormalities of the hepatic, renal, cardiovascular,
             respiratory, gastro-intestinal, hematological, endocrine or metabolic systems which
             might complicate assessment of the tolerability of the study medication.
Clinical trial NCT00706589 (phase 3, status: completed)
Conditions: chronic motor or vocal tic disorder, tourette's disorder
ICD codes: F95.2
Drugs: aripiprazole, placebo
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients who can provide an assent form signed by themselves and informed consent form
             by their legal representatives prior to performing of any study procedures.

          2. Male or female children and adolescents aged 6 to 18 years

          3. Patients who are diagnosed with chronic tic disorders(Motor or Phonic) or Tourette's
             disorder according to DSM-IV(Diagnostic and Statistical Manual of Mental
             Disorders-Fourth Edition)(using K-SADS-PL-K (Kiddle-Schedule for Affective Disorders
             and Schizophrenia,Present and Lifetime Version-Korean version)) and require drug
             therapy.

          4. The total tic score of the K-YGTSS (Korean version of Yale Global Tic Severity
             Scale)is more than 22 at baseline

        Exclusion Criteria:

          1. Patients with secondary tic symptoms accompanied by Tardive tics, Huntington disease,
             neuroacanthocytosis, mental retardation, or autism

          2. Patients with IQ (Intelligence quotient) (assessed using KEDI-WISC (Korean educational
             Development Institute-Wechsler Intelligence Scale for children)) 70 and lower than 70

          3. Patients with a history of neuroleptic malignant syndrome

          4. Patients with antipsychotic or alcohol use disorder (abuse, dependence, and/or
             withdrawal) according to DSM-IV criteria for the past 3 months

          5. Patients with a history of allergy or hypersensitivity reaction to aripiprazole

          6. Patients with a history of resistance to treatment with antipsychotics

          7. Patients who have participated in another clinical study within 1 month prior to
             screening

          8. Patients who have previously taken aripiprazole or participated in a clinical study
             with aripiprazole
Clinical trial NCT00352053 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: tenofovir df, placebo
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Major Inclusion Criteria:

          -  Weight ≥ 35 kg

          -  Documented laboratory diagnosis of HIV infection

          -  Plasma HIV-1 RNA ≥ 1000 copies/mL

          -  Prior antiretroviral treatment experience with at least 2 antiretroviral drug classes

          -  Naive to tenofovir DF

          -  Absence of K65R mutation on genotypic testing

        Exclusion Criteria:

          -  Patients requiring didanosine in background regimen

          -  Prior history of significant renal disease

          -  Prior history of significant bone disease
Clinical trial NCT00321490 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine fumarate, duloxetine
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has a documented clinical diagnosis of Major Depressive Disorder.

          -  Be able to understand and comply with the requirements of the study.

          -  Able to understand and provide written informed consent

        Exclusion Criteria:

          -  Patients (female) must not be pregnant or lactating

          -  Current or past diagnosis of stroke or transient ischemic attack (TIA).
Clinical trial NCT00411554 (phase 3, status: completed)
Conditions: diabetes mellitus, non-insulin-dependent
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: sitagliptin phosphate, comparator: voglibose
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients have type 2 diabetes mellitus on diet/exercise therapy

        Exclusion Criteria:

          -  Patients have type 1 diabetes mellitus
Clinical trial NCT00202566 (phase 3, status: completed)
Conditions: angina pectoris
ICD codes: I20.9, I20.1, I20.8, I25.10, I25.810, I25.110, I25.119
Drugs: ivabradine
SMILES: COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic stable angina pectoris

          -  Documented coronary artery disease

          -  Previous treatment with atenolol or other beta-blocker agent

          -  Exercise tolerance test positivity and stability

        Exclusion Criteria:

          -  Heart rate < 60 bpm

          -  Congestive heart failure
Clinical trial NCT00330772 (phase 3, status: completed)
Conditions: coronary artery disease, coronary artery bypass grafting
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, I25.84, I25.41, I25.42, Z98.61, Q24.5, T46.3X6S, I25.82
Drugs: aspirin, clopidogrel
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18 years of age or older

          -  Undergoing on-pump, elective coronary artery bypass grafting with at least 2 free
             grafts

          -  Patient able to give informed consent

        Exclusion Criteria:

          -  planned date of surgery is <5 days from planned recruitment date

          -  patient has clear indication for anticoagulation (eg. mechanical heart valve, atrial
             fibrillation) or ADP receptor antagonist (eg. drug-eluting stent)

          -  allergy to or intolerance of aspirin or clopidogrel

          -  history of bleeding diathesis, significant GI bleed, ICH, or liver failure

          -  Patient has known renal failure or contraindication for Cardiac CT Angio

          -  Patient has had previous cardiac surgery
Clinical trial NCT01069289 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: budesonide/formoterol (symbicort turbuhaler), formoterol (oxis turbuhaler)
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  A current clinical diagnosis of Chronic Obstructive Pulmonary Disease

          -  Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years

          -  A smoking history of at least 10 pack years

        Exclusion Criteria:

          -  History and/or current clinical diagnosis of asthma

          -  History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis